Published in Curr Opin HIV AIDS on May 01, 2007
Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc Natl Acad Sci U S A (2007) 1.00
Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected. J Infect Dis (2014) 0.76
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol (2008) 7.14
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science (2007) 4.60
Advantage of rare HLA supertype in HIV disease progression. Nat Med (2003) 4.08
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology (2004) 3.98
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med (2010) 3.44
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One (2009) 3.40
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One (2007) 2.61
Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol (2003) 2.53
A jumping profile Hidden Markov Model and applications to recombination sites in HIV and HCV genomes. BMC Bioinformatics (2006) 2.25
HIV sequence databases. AIDS Rev (2003) 2.20
HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog (2009) 2.15
Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology (2011) 2.13
Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol (2003) 2.07
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest (2012) 2.05
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS (2004) 1.89
Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One (2010) 1.77
HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol (2005) 1.76
The role of recombination in the emergence of a complex and dynamic HIV epidemic. Retrovirology (2010) 1.69
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One (2013) 1.65
HIV-1 vaccine development after STEP. Annu Rev Med (2010) 1.64
jpHMM: improving the reliability of recombination prediction in HIV-1. Nucleic Acids Res (2009) 1.61
Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol (2006) 1.59
jpHMM at GOBICS: a web server to detect genomic recombinations in HIV-1. Nucleic Acids Res (2006) 1.58
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2013) 1.51
Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol (2008) 1.51
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol (2010) 1.51
High-throughput flow cytometry data normalization for clinical trials. Cytometry A (2013) 1.47
Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog (2011) 1.42
Single nucleotide polymorphism array analysis of flow-sorted epithelial cells from frozen versus fixed tissues for whole genome analysis of allelic loss in breast cancer. Am J Pathol (2002) 1.39
Epitope escape mutation and decay of human immunodeficiency virus type 1-specific CTL responses. J Immunol (2003) 1.36
Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. J Virol (2007) 1.32
Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J Virol (2006) 1.30
Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics (2008) 1.30
Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis (2004) 1.28
Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol (2013) 1.24
Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS (2002) 1.24
Los alamos hepatitis C immunology database. Appl Bioinformatics (2005) 1.23
Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology (2002) 1.18
Coping with viral diversity in HIV vaccine design: a response to Nickle et al. PLoS Comput Biol (2008) 1.17
Mycobacterium tuberculosis--heterogeneity revealed through whole genome sequencing. Tuberculosis (Edinb) (2012) 1.17
Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities. J Acquir Immune Defic Syndr (2003) 1.10
Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. J Gen Virol (2010) 1.05
Analytic insights into the population level impact of imperfect prophylactic HIV vaccines. J Acquir Immune Defic Syndr (2007) 0.97
Measuring the public-health impact of candidate HIV vaccines as part of the licensing process. Lancet Infect Dis (2008) 0.95
A multiple-alignment based primer design algorithm for genetically highly variable DNA targets. BMC Bioinformatics (2013) 0.94
A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. J Immunol Methods (2013) 0.93
Fitness costs of rifampicin resistance in Mycobacterium tuberculosis are amplified under conditions of nutrient starvation and compensated by mutation in the β' subunit of RNA polymerase. Mol Microbiol (2014) 0.93
Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage. PLoS One (2012) 0.92
nCal: an R package for non-linear calibration. Bioinformatics (2013) 0.92
The evolutionary rate dynamically tracks changes in HIV-1 epidemics: application of a simple method for optimizing the evolutionary rate in phylogenetic trees with longitudinal data. Epidemics (2009) 0.89
A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein. PLoS Comput Biol (2013) 0.88
Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains. Clin Vaccine Immunol (2012) 0.84
Viral genome analysis and knowledge management. Methods Mol Biol (2013) 0.81
Fragmentation of SIV-gag vaccine induces broader T cell responses. PLoS One (2012) 0.81
HIV classification using the coalescent theory. Bioinformatics (2010) 0.81
T cell responses in HIV type 1-infected adolescent minorities share similar epitope specificities with whites despite significant differences in HLA class I alleles. AIDS Res Hum Retroviruses (2003) 0.81
Comparing and combining data across multiple sources via integration of paired-sample data to correct for measurement error. Stat Med (2012) 0.81
Correction: Esophageal Adenocarcinoma and Its Rare Association with Barrett's Esophagus in Henan, China. PLoS One (2015) 0.80
Mother-to-child transmission in the United States of subtypes D and A/G human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2002) 0.80
The spread of HIV in Africa. J Neurovirol (2005) 0.80
Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop. J Acquir Immune Defic Syndr (2007) 0.79
A transdimensional Bayesian model for pattern recognition in DNA sequences. Biostatistics (2008) 0.78
The automated counting of spots for the ELISpot assay. J Immunol Methods (2006) 0.78
Modeling partially effective HIV vaccines in vitro. J Infect Dis (2004) 0.78
Building on the past to define an efficient path to an HIV vaccine. Expert Rev Vaccines (2011) 0.77
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathog (2017) 0.75
A plea for justice for jailed medical workers. Science (2006) 0.75
Research on infectious disease dynamics. Introduction. Epidemics (2009) 0.75